Preparation useful for, and method for treatment of neonatal alloimmune thrombocytopenia (NAIT)
A preparation useful for, and a method for the prophylactic treatment of women post-childbirth in order to avoid immunization and antibody production, which could induce NAIT and fetal/neonatal bleeding in subsequent pregnancies comprising administering a preparation containing antibodies to HPA1a within 72 hours after delivery in the first non-compatible pregnancy.
1. A method for the prophylactic treatment of neonatal alloimmune thrombocytopenia (NAIT), the method comprising the step of
administering to a pregnant woman who is negative for the human platelet antigen HPA 1a, as well as negative for antibodies specific to the human platelet antigen HPA 1a, and who has received HPA 1a positive foetal platelets into her circulation from her HPA 1a positive foetus, a preparation comprising a sufficient quantity of antibodies to HPA 1a so as to substantially inhibit the woman's immune system from producing antibodies to HPA 1a wherein the preparation is administered to the woman before her own immune system starts to produce her own antibodies to the HPA 1a of the foetal platelets.
2. The method of claim 1 , wherein the preparation is administered within 72 hours of receiving HPA 1a positive foetal platelets into her circulation.
3. The method of claim 2 , wherein the preparation comprises Immunoglobulin G plasma derived from human plasma.
4. The method of claim 2 , wherein the preparation that is administered comprises an immunoglobulin G (IgG) concentrate derived from human plasma containing antibodies specific to human platelet antigen HPA 1a.
5. The method of claim 4 , comprising the further step of determining whether the newborn is positive for human platelet antigen HPA 1a prior to administering the preparation to the woman.
6. A method for the prophylactic treatment of neonatal alloimmune thrombocytopenia (NAIT), the method comprising the step of:
administering to a woman who is negative for the human platelet antigen HPA 1a, as well as negative for antibodies specific to the human platelet antigen HPA 1a, and who has received or who may receive HPA 1a positive foetal platelets into her circulation at delivery of her HPA 1a positive child, a preparation comprising a sufficient quantity of antibodies to HPA 1a so as to substantially inhibit the woman's immune system from producing antibodies to HPA 1a, wherein the preparation is administered to the woman within 72 hours of delivery.
7. The method of claim 6 , wherein the preparation is administered up to 72 hours after delivery.
8. The method of claim 6 , wherein the preparation is administered up to 72 hours before delivery.
9. The method of claim 6 , wherein the preparation comprises Immunoglobulin G plasma derived from human plasma.
10. The method of claim 6 , wherein the preparation that is administered comprises an Immunoglobulin G (IgG) concentrate derived from human plasma containing antibodies specific to human platelet antigen HPA 1a.
11. The method of claim 6 , comprising the further step of determining whether the newborn is positive for human platelet antigen HPA 1a prior to administering the preparation to the woman.